| Multiple Sclerosis, Relapsing-Remitting
Zeposia vs Briumvi
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, relapsing-remitting.Deep comparison between: Zeposia vs Briumvi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBriumvi has a higher rate of injection site reactions vs Zeposia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Briumvi but not Zeposia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zeposia
Briumvi
At A Glance
Oral
Once daily
S1P receptor modulator
IV infusion
Every 24 weeks
Anti-CD20 monoclonal antibody
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Ulcerative Colitis
- Multiple Sclerosis, Relapsing-Remitting
- Clinically isolated syndrome
- Multiple Sclerosis, Secondary Progressive
Dosing
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome, Ulcerative Colitis Initiate with 7-day titration (0.23 mg once daily days 1-4, 0.46 mg once daily days 5-7); maintenance dose 0.92 mg orally once daily starting day 8; patients with mild or moderate hepatic impairment (Child-Pugh class A or B) take 0.92 mg once every other day after titration.
Multiple Sclerosis, Relapsing-Remitting; Clinically isolated syndrome; Multiple Sclerosis, Secondary Progressive 150 mg IV infusion (first infusion), followed by 450 mg IV infusion 2 weeks later, then 450 mg IV every 24 weeks; pre-medicate with methylprednisolone (or equivalent corticosteroid) and antihistamine before each infusion.
Contraindications
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure in the last 6 months
- Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
- Severe untreated sleep apnea
- Concurrent use of a monoamine oxidase (MAO) inhibitor
- Active HBV infection
- History of life-threatening infusion reaction to ublituximab-xiiy
Adverse Reactions
Most common (>=4%) Upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, hypertension (MS); liver test increased, upper respiratory infection, headache (UC)
Serious Infections, progressive multifocal leukoencephalopathy, bradyarrhythmia and AV conduction delays, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, cutaneous malignancies, posterior reversible encephalopathy syndrome
Postmarketing Liver injury
Most common (>=10%) Infusion reactions, upper respiratory tract infections
Serious Infusion reactions, infections, reduction in immunoglobulins, liver injury
Postmarketing Liver injury, progressive multifocal leukoencephalopathy
Pharmacology
Ozanimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in MS and ulcerative colitis is unknown but may involve reduced lymphocyte migration into the CNS and intestine.
Anti-CD20 chimeric monoclonal IgG1 antibody with reduced fucose content; binds CD20 on pre-B and mature B lymphocytes and causes cell lysis via antibody-dependent cellular cytolysis and complement-dependent cytolysis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zeposia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Briumvi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Zeposia
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (3/8)
Briumvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Zeposia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Briumvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Zeposia.
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZeposiaView full Zeposia profile
BriumviView full Briumvi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.